11
Transient HAART During PHI Prolongs the Total Time Off HAART in Patients Presenting with PHI: Data from the Dutch Primo-SHM Cohort R. Steingrover, S. Jurriaans,
Switching from first ART regimen while virologically suppressed is common in the CANOC cohort and is associated with increased risk of subsequent virologic.
Should We be Measuring Mortality in HIV Clinical Programs? September 13 th, 2012 Steven Johnson MD Director, University of Colorado HIV/AIDS Clinical Program;
R. Steingrover, S. Jurriaans, J. Lange, J.M. Prins on behalf of the Primo-SHM study group
IAS 2011_ Abstract # WEPDB0102 Sustained Efficacy and Tolerability of Raltegravir after 240 Weeks of Combination ART in Treatment- Naive HIV-1 Infected.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
Level of HIV-1 unspliced RNA in PBMC: a longitudinal marker of infection progression
The Hippocratic oath in practice: the ethics, challenges and strategies for healthcare worker reporting “There’s really no such thing as the voiceless….only.
Should We be Measuring Mortality in HIV Clinical Programs? September 13 th , 2012
Gabriel M. Anabwani, Executive Director Elizabeth Lowenthal, Associate Director
M Hull, A Cescon, JM Raboud, MB Klein , S Walmsley,
